Brain Trust Bio (BTB), a pioneering company in the field of central nervous system (CNS) disease treatment, has been granted the go-ahead to initiate Phase I clinical trials.

Astria Therapeutics has reported promising preliminary results from the ALPHA-STAR Phase 1b/2 clinical trial of STAR-0215.

Stoke Therapeutics has reported significant findings from its Phase 1/2a clinical trials and open-label extension studies for STK-001.

Rhythm Pharmaceuticals has commenced dosing for its Phase 1 clinical trial of RM-718.

Valneva SE launched a Phase 1 clinical study to evaluate the safety and ability to provoke an immune response of their Zika virus vaccine candidate, VLA1601.

Tectonic Therapeutic has commenced a Phase 1B clinical trial for TX45, a novel long-acting relaxin-Fc fusion protein.

Viking Therapeutics has reported significant weight loss outcomes from a Phase 1 clinical trial of VK2735, a new dual GLP-1/GIP receptor agonist.

CIN-110 is being developed by CinFina Pharma, a company within the CinRx portfolio that focuses on treatments for obesity and metabolic disorders.

The study is assessing the combination of voruciclib, a CDK9 inhibitor, and venetoclax, a BCL2 inhibitor, for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML).

This submission is for a Phase 1b clinical trial of TU7710, a novel recombinant activated factor VII (rFVIIa), intended to treat hemophilia A or B patients with inhibitors.

Opus Genetics reported positive results from its Phase 1/2 clinical trial. The trial is testing OPGx-LCA5.

Stoke Therapeutics has announced encouraging results from its Phase I/IIa clinical trial for a treatment candidate, STK-001, for Dravet syndrome.